A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo Co., Ltd., Daiichi Sankyo Company, Limited.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

138actual

Sites

Countries

Australia, Belgium, Brazil +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-12-17

actual

When the study began enrolling

Primary completion

2023-08-16

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-06-01

estimated

The whole study's end, after follow-up

First posted

2020-09-21

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-03

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Metastatic Breast Cancer

Interventions

Drug: Trastuzumab deruxtecan — also filed as DS-8201a, T-DXd
Drug: Durvalumab — also filed as MEDI4736
Drug: Paclitaxel — also filed as Taxol A
Drug: Capivasertib — also filed as AZD5363
Drug: Anastrozole — also filed as Anastrozol
Drug: Fulvestrant
Drug: Capecitabine

Primary outcomes

what the primary-completion date above is the date OF

Occurrence of adverse events (AEs)- Part 1

measured Up to follow-up period, approximately 24 months

Occurrence of serious adverse events (SAEs)- Part 1

measured Up to follow-up period, approximately 24 months

Occurrence of adverse events (AEs)- Part 2

measured Up to follow-up period, approximately 24 months

Occurrence of serious adverse events (SAEs)- Part 2

measured Up to follow-up period, approximately 24 months

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed